Holen Sie sich die Stockscreener-App
350.16
1.45%
-5.14
Handel nachbörslich:
350.42
0.26
+0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$355.30
Offen:
$354.25
24-Stunden-Volumen:
2.08M
Relative Volume:
0.75
Marktkapitalisierung:
$188.76B
Einnahmen:
$36.74B
Nettoeinkommen (Verlust:
$7.71B
KGV:
24.60
EPS:
14.2333
Netto-Cashflow:
$8.10B
1W Leistung:
+0.10%
1M Leistung:
+0.68%
6M Leistung:
+15.44%
1J Leistung:
+26.28%
1-Tages-Spanne:
$350.02
$356.90
1-Wochen-Bereich:
$344.21
$356.90
52-Wochen-Spanne:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
350.16 | 191.53B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to unlock new upside? - AD HOC NEWS
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
What to Expect From Amgen's Next Quarterly Earnings Report - Barchart
Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside? - AD HOC NEWS
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive new upside? - AD HOC NEWS
Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN - MarketBeat
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer - GlobeNewswire Inc.
Pfizer (PFE) and Amgen (AMGN) Expand Presence in Hong Kong - GuruFocus
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (PFE:NYSE) - Seeking Alpha
Amgen Inc. Trade Ideas — LSE:0R0T - TradingView
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive sustained upside? - AD HOC NEWS
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy - Insider Monkey
Wealth Enhancement Trust Services Inc. Takes $1.58 Million Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reconsider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Oak Harvest Investment Services Reduces Stake in Amgen Inc. $AMGN - MarketBeat
GF Fund Management CO. LTD. Acquires 6,216 Shares of Amgen Inc. $AMGN - MarketBeat
Asset Management One Co. Ltd. Has $114.31 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Laps the Stock Market: Here's Why - Yahoo Finance Singapore
AMGEN INC: SUBMITS SEC FILING FOR COMMON STOCK OFFERING BY SELLING SECURITYHOLDERS - Intellectia AI
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
UBS Sees Continued Upside in Amgen (AMGN), Lifts Target to $400 - Insider Monkey
Amgen Inc. $AMGN Shares Sold by Whittier Trust Co. - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $186.70 Million Stake in Amgen Inc. $AMGN - MarketBeat
Assessing Whether Amgen (AMGN) Still Looks Undervalued After Recent Share Price Pullback - simplywall.st
Argo Wealth Advisory LLC Purchases New Shares in Amgen Inc. $AMGN - MarketBeat
AE Wealth Management LLC Has $43.90 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Federal Circuit Distinguishes Amgen in Reversal of Invalidation of Teva Headache Treatment Patents - IPWatchdog.com
Idiopathic Pulmonary Fibrosis Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GSK, Amgen, Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant - Barchart.com
Amgen Shares Acquired by Lbp Am Sa - National Today
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
KBC Group NV Has $187.27 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Lbp Am Sa - MarketBeat
Amgen Extends Cuala GAA Title Sponsorship Through 2029 - Sport for Business
Amgen Inc. $AMGN Shares Purchased by Farther Finance Advisors LLC - MarketBeat
Amgen Inc. $AMGN Shares Bought by Cwm LLC - MarketBeat
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen Inc. stock (US0311621009): Is its biotech innovation edge strong enough for steady gains? - AD HOC NEWS
2 Reasons to Like AMGN and 1 to Stay Skeptical - Yahoo Finance
Amgen Inc. stock (US0311621009): Is its biotech innovation edge strong enough to unlock new upside? - AD HOC NEWS
Amgen And Zai Lab Trial Tests DLL3 Combo As Valuation Looks Undemanding - Yahoo Finance
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to sustain long-term growth? - AD HOC NEWS
Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story - simplywall.st
Assetmark Inc. Increases Stake in Amgen Inc. - National Today
Assetmark Inc. Buys 14,341 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
AMGN Maintained by UBS -- Price Target Raised to $400 - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $400.00 - MarketBeat
Morgan Stanley Raises Amgen (AMGN) Target Ahead of Q1, Truist Lifts Outlook on Pipeline Strength - Insider Monkey
‘Community Day Presented by Amgen’ Mobilizes Volunteers to Touch Up Greater Los Angeles Ahead of FIFA World Cup 2026 - Amgen
Beat the Market the Zacks Way: FirstEnergy, Seanergy Maritime, Amgen in Focus - Yahoo Finance
HBW Advisory Services LLC Has $2.07 Million Position in Amgen Inc. $AMGN - MarketBeat
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):